布地奈德联合不同药物雾化吸入治疗6～10岁慢性持续期儿童哮喘的效果
|
摘要
目的探讨布地奈德联合不同药物雾化吸入治疗6～10岁慢性持续期儿童哮喘的效果。方法将我院收治的82例6～10岁慢性持续期哮喘患儿随机分为对照组和观察组,每组41例。在常规治疗基础上,对照组予以布地奈德+特布他林进行治疗,观察组采用布地奈德+特布他林+异丙托溴铵进行治疗。比较两组的治疗效果。结果观察组的治疗总有效率明显高于对照组,夜间哮喘发作率显著低于对照组(P<0.05)。观察组患儿气喘、咳嗽、哮鸣音消失时间及住院时间均显著短于对照组(P<0.05)。治疗后,两组患儿的FEV1、FEV1%和FEV1/FVC均明显升高,且观察组高于对照组(P<0.05)。两组患儿治疗过程中均未发生严重不良反应。结论与布地奈德联合特布他林相比,布地奈德联合特布他林和异丙托溴铵雾化吸入在提高儿童慢性持续期哮喘的治疗效果、改善肺功能、降低夜间哮喘发作等方面更具优势。
Objective To explore the effect of aerosol inhalation therapy of budesonide combined with different drugs on6-10 years old children with chronic persistent asthma. Methods Eighty-two children with chronic persistent asthma aged6-10 treated in our hospital were randomly divided into control group and observation group, with 41 cases in each group.On the basis of routine treatment, the control group was treated with budesonide+terbutaline, while the observation group was treated with budesonide +terbutaline +ipratropium bromide. The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was significantly higher than that in the control group,and the attack rate of asthma at night was significantly lower than that in the control group(P<0.05). The time of asthma,cough and wheezing disappearance, hospitalization time in the observation group were significantly shorter than those in the control group(P<0.05). After treatment, the levels of FEV1, FEV1% and FEV1/FVC in both groups significantly increased,and those of the observation group were higher than the control group(P<0.05). There were no serious adverse reactions during the treatment in both groups. Conclusion Compared with budesonide combined with terbutaline, budesonide combined with terbutaline and ipratropium bromide aerosol inhalation has more advantages in improving the therapeutic effect of children's chronic persistent asthma, improving pulmonary function and reducing nighttime asthma attack.
Objective To explore the effect of aerosol inhalation therapy of budesonide combined with different drugs on6-10 years old children with chronic persistent asthma. Methods Eighty-two children with chronic persistent asthma aged6-10 treated in our hospital were randomly divided into control group and observation group, with 41 cases in each group.On the basis of routine treatment, the control group was treated with budesonide+terbutaline, while the observation group was treated with budesonide +terbutaline +ipratropium bromide. The therapeutic effects of the two groups were compared.Results The total effective rate of treatment in the observation group was significantly higher than that in the control group,and the attack rate of asthma at night was significantly lower than that in the control group(P<0.05). The time of asthma,cough and wheezing disappearance, hospitalization time in the observation group were significantly shorter than those in the control group(P<0.05). After treatment, the levels of FEV1, FEV1% and FEV1/FVC in both groups significantly increased,and those of the observation group were higher than the control group(P<0.05). There were no serious adverse reactions during the treatment in both groups. Conclusion Compared with budesonide combined with terbutaline, budesonide combined with terbutaline and ipratropium bromide aerosol inhalation has more advantages in improving the therapeutic effect of children's chronic persistent asthma, improving pulmonary function and reducing nighttime asthma attack.
引文
[1]程哲,夏杰,张春玲,等.支气管哮喘患者诱导痰内巨噬细胞衍生趋化因子的水平及其意义[J].中华结核和呼吸杂志,2011,34(3):217-218.
[2]孙益,万力生,李佳曦,等.基于代谢组学的支气管哮喘生物标志物研究进展[J].安徽医药,2018,22(3):395-398.
[3]魏艳,刘芬,程欣,等.噻托溴铵联合布地奈德福莫特罗对中度哮喘患者β2受体的调节作用[J].第三军医大学学报,2013,35(11):1152-1155.
[4]洪建国,鲍一笑.重视儿童支气管哮喘的规范化诊治[J].中华儿科杂志,2016,54(3):161-162.
[5]THEODOROPOULOS DS,LOCKEY RF,BOYCE HW JR,et al.Gastroesophageal reflux and asthma:a review of pathogenesis,diagnosis,and therapy[J].Allergy,2015,54(7):651-661.
[6]GIRODET PO,OZIER A,BARA I,et al.Airway remodeling in asthma:new mechanisms and potential for pharmacological intervention[J].Pharmacol Ther,2011,130(3):325-337.
[7]张静,陆桥.异丙托溴铵联合布地奈德与沙丁胺醇雾化吸入治疗儿童哮喘40例[J].陕西医学杂志,2015,44(4):505-506.
[8]杨启慧.布地奈德联合特布特林雾化吸入治疗儿童支气管哮喘急性发作的临床观察[J].中国医药导刊,2012,14(3):448-449.
[9]张腊娣.特布他林联合布地奈德雾化吸入治疗重症哮喘的临床疗效[J].江苏医药,2010,36(19):2326-2327.
[10]G?KALP A ?,BI?ER S?IR ANECI R.Efficiacy of nebulized ipratropium bromide in the treatment of acute asthma in children:randomised,double blind,placebo-controlled trial[J].Nobel Medicus,2013,9(1):67-75.S,
[2]孙益,万力生,李佳曦,等.基于代谢组学的支气管哮喘生物标志物研究进展[J].安徽医药,2018,22(3):395-398.
[3]魏艳,刘芬,程欣,等.噻托溴铵联合布地奈德福莫特罗对中度哮喘患者β2受体的调节作用[J].第三军医大学学报,2013,35(11):1152-1155.
[4]洪建国,鲍一笑.重视儿童支气管哮喘的规范化诊治[J].中华儿科杂志,2016,54(3):161-162.
[5]THEODOROPOULOS DS,LOCKEY RF,BOYCE HW JR,et al.Gastroesophageal reflux and asthma:a review of pathogenesis,diagnosis,and therapy[J].Allergy,2015,54(7):651-661.
[6]GIRODET PO,OZIER A,BARA I,et al.Airway remodeling in asthma:new mechanisms and potential for pharmacological intervention[J].Pharmacol Ther,2011,130(3):325-337.
[7]张静,陆桥.异丙托溴铵联合布地奈德与沙丁胺醇雾化吸入治疗儿童哮喘40例[J].陕西医学杂志,2015,44(4):505-506.
[8]杨启慧.布地奈德联合特布特林雾化吸入治疗儿童支气管哮喘急性发作的临床观察[J].中国医药导刊,2012,14(3):448-449.
[9]张腊娣.特布他林联合布地奈德雾化吸入治疗重症哮喘的临床疗效[J].江苏医药,2010,36(19):2326-2327.
[10]G?KALP A ?,BI?ER S?IR ANECI R.Efficiacy of nebulized ipratropium bromide in the treatment of acute asthma in children:randomised,double blind,placebo-controlled trial[J].Nobel Medicus,2013,9(1):67-75.S,